



## Dr Klaartje Bel Kok PhD, MRCP (UK), MBBS, MSc

Dr. Klaartje Bel Kok is a Consultant Gastroenterologist and the **Clinical Lead for Gastroenterology** at Barts Health NHS Trust (The Royal London Hospital), as well as a consultant at **Cleveland Clinic London**. With over two decades of clinical and research experience, she is a recognized leader in the management of IBD, with particular expertise in adolescent-to-adult transition, pregnancy in IBD, and intestinal ultrasound.

She is an **Honorary Senior Clinical Lecturer** at Queen Mary University of London and a co-author of the **British Society of Gastroenterology (BSG) guidelines on IBD**. Dr. Bel Kok has also served as a long-term member of the **United European Gastroenterology (UEG) Education Committee**, helping to shape gastroenterology training across Europe.

### Professional Qualifications

2016	Certificate of Completion of Training (Gastroenterology), UK
2010	MRCP (UK)
2009	PhD, University of Groningen, Netherlands
2025	IBUS certification (modules 1-3) in intestinal ultrasound

### Current Posts

2016	Consultant Gastroenterologist and Clinical Lead gastroenterology Barts Health NHS Trust, The Royal London Hospital
2016	Honorary Senior Clinical Lecturer Centre for Immunobiology, Blizard Institute, Queen Mary University of London
2022	Consultant Gastroenterologist, Cleveland Clinic London

### Research

Chief investigator	<ul style="list-style-type: none"><li>• IBD and Pregnancy studies – CI of several ongoing clinical studies and co-supervisor of MD student. Queen Mary University of London / Barts Health</li><li>• UK CI for VE202 phase commercial study</li></ul>
Principal investigator	<ul style="list-style-type: none"><li>• Of multiple IBD investigator lead clinical trials, including PROFILE; Bioresource; UNDIES, , IBD-BOOST, Gondomar, Ocean, Clarity, Meerkat</li></ul>
Co-investigator	<ul style="list-style-type: none"><li>• For multiple IBD commercial and investigator led trials.</li></ul>



PhD supervisor

Current actively recruiting trials include VERDICT, ADDapt, PARIS, M14 Upadacatinib studies, M16 Risankizumab studies, IBDResponse, Thames IBD, STAR.

- The impact of IL-12 and IL-23 blockade on the development, differentiation and function of intestinal monocyte derived cells in Crohn's disease. QMUL/Barts & The London School of Medicine & Dentistry

## Selection of Publications

- Moran GW, et al. British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. *Gut*. 2025 Jun 23;74(Suppl 2):s1-s101. doi: 10.1136/gutjnl-2024-334395.
- Noor NM, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. *Lancet Gastroenterol Hepatol*. 2024 Feb 21:S2468-1253(24)00034-7. doi: 10.1016/S2468-1253(24)00034-7
- Gordon H, et al. Human Intestinal Dendritic Cells Can Overcome Retinoic Acid Signaling to Generate Proinflammatory CD4 T Cells with Both Gut and Skin Homing Properties. *J Immunol*. 2024 Jan 1;212(1):96-106. doi: 10.4049/jimmunol.2300340. PMID: 37955427.
- Plumb AA, et al. Small Bowel Motility Quantified by Cine MRI to Predict Longer-Term Response in Patients with Crohn's Disease Commencing Biological Therapy: The Motility Study. *Inflamm Bowel Dis*. 2025 Mar 7:izaf023. doi: 10.1093/ibd/izaf023. Epub ahead of print. PMID: 40053679.
- Darie AM, et al. BSG 2024 IBD guidelines protocol (standard operating procedures). *BMJ Open Gastroenterol*. 2023 Feb;10(1):e001067. doi: 10.1136/bmjgast-2022-001067.
- Kok KB, et al. Understanding and managing psychological disorders in patients with inflammatory bowel disease: a practical guide. *Frontline Gastroenterol*. 2022 May 24;14(1):78-86. doi: 10.1136/flgastro-2022-102094. eCollection 2023.
- Alexander JL, et al. VIP study investigators. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. *Lancet Gastroenterol Hepatol*. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9.
- Lin S, et al. CLARITY IBD study. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. *Nat Commun*. 2022 Mar 16;13(1):1379. doi: 10.1038/s41467-022-28517-z.
- Kennedy NA, et al. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. *Gut*. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22.
- Curciarello R, et al. Human Neutrophil Elastase Proteolytic Activity in Ulcerative Colitis Favors the Loss of Function of Therapeutic Monoclonal Antibodies. *J Inflamm Res*. 2020 May 22;13:233-243. doi: 10.2147/JIR.S234710. eCollection 2020.
- Biancheri P, et al. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis



factor in the mucosa of patients with inflammatory bowel disease. *Gastroenterology*. 2015 Nov;149(6):1564-1574.e3. doi: 10.1053/j.gastro.2015.07.002. Epub 2015 Jul 11.

## Book chapters and other publications

**Kok K.** Nutrition Chapter. Kumar and Clark's Clinical Medicine, 10th Edition; Kok K, Ibarra A, Lindsay J. Emerging therapies in IBD. Book chapter in IBD nursing manual. Elsevier 2019 and 2025

## Reviewer for

European Crohn's and Colitis Organisation; British Society for Gastroenterology; Alimentary Pharmacology and Therapeutics; Journal of Crohn's and colitis; Frontline Gastroenterology